WO2011043519A3 - Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor - Google Patents

Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor Download PDF

Info

Publication number
WO2011043519A3
WO2011043519A3 PCT/KR2010/001633 KR2010001633W WO2011043519A3 WO 2011043519 A3 WO2011043519 A3 WO 2011043519A3 KR 2010001633 W KR2010001633 W KR 2010001633W WO 2011043519 A3 WO2011043519 A3 WO 2011043519A3
Authority
WO
WIPO (PCT)
Prior art keywords
serotonin
sulfonamide derivatives
receptor antagonist
reuptake inhibitor
serotonin reuptake
Prior art date
Application number
PCT/KR2010/001633
Other languages
French (fr)
Other versions
WO2011043519A2 (en
Inventor
Ae Nim Pae
Hyunah Choo
Yong Seo Cho
Sun Ah Jun
Hye Jin Cho
Woo Kyu Park
Jeong Min Kim
Original Assignee
Korea Institute Of Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute Of Science And Technology filed Critical Korea Institute Of Science And Technology
Publication of WO2011043519A2 publication Critical patent/WO2011043519A2/en
Publication of WO2011043519A3 publication Critical patent/WO2011043519A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Abstract

The present invention relates to sulfonamide derivatives as a serotonin receptor antagonist and serotonin reuptake inhibitor and a pharmaceutically acceptable salt thereof. The sulfonamide derivatives have serotonin 5-HT2A and 5-HT2C receptor antagonizing and serotonin reuptake inhibiting functions, and thus may be efficiently applied to a CNS-related disease such as depression, obesity, psychosis, schizophrenia, suicidal tendency, anxiety, obsessional neurosis, migraine, appetite disorders, sleep disorders, stroke, and withdrawal symptoms caused by drug abuse.
PCT/KR2010/001633 2009-10-09 2010-03-17 Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor WO2011043519A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090096094A KR101152659B1 (en) 2009-10-09 2009-10-09 Novel sulfonamide compounds as serotonin receptor antagonists and serotonin transporter inhibitor
KR10-2009-0096094 2009-10-09

Publications (2)

Publication Number Publication Date
WO2011043519A2 WO2011043519A2 (en) 2011-04-14
WO2011043519A3 true WO2011043519A3 (en) 2011-10-20

Family

ID=43857239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001633 WO2011043519A2 (en) 2009-10-09 2010-03-17 Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor

Country Status (2)

Country Link
KR (1) KR101152659B1 (en)
WO (1) WO2011043519A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL395470A1 (en) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Alicyclic amines sulfonamide derivatives for the treatment of diseases of the central nervous system
FR3030516B1 (en) * 2014-12-19 2019-12-27 Galderma Research & Development BICYCLE SULFONAMIDE DERIVATIVES AS INVERTED AGONISTS OF THE ORPHAN GAMMA RECEPTOR ASSOCIATED WITH ROR GAMMA (T) RETINOIDS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036595A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US20080200461A1 (en) * 2007-02-20 2008-08-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407180A (en) * 2003-02-14 2006-02-07 Lilly Co Eli Compound, pharmaceutical composition, methods for modulating a peroxisome proliferator-activated receptor, for treating or preventing a disease or condition, for lowering blood glucose in a mammal, for treating or preventing diabetes mellitus, cardiovascular disease, and syndrome x in a mammal. , and, use of a compound
US20060025445A1 (en) 2004-08-02 2006-02-02 Xiang Jason S 11-Beta HSD1 inhibitors
CN101426788A (en) 2006-04-20 2009-05-06 詹森药业有限公司 Substituted pyrazinone derivatives for use as a medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036595A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US20080200461A1 (en) * 2007-02-20 2008-08-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof

Also Published As

Publication number Publication date
KR101152659B1 (en) 2012-06-15
WO2011043519A2 (en) 2011-04-14
KR20110038903A (en) 2011-04-15

Similar Documents

Publication Publication Date Title
NO2020042I1 (en) Entrektinib or isomers, tautomers, or pharmaceutically acceptable salts thereof
MX2007004794A (en) Thienopyridines as allosteric potentiators of the m4 muscarinic receptor.
IL214049A0 (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof
WO2008012622A3 (en) Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
ZA200706354B (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2007150025A3 (en) Purinone derivatives as hm74a agonists
WO2010148207A3 (en) Processes for the preparation of 5-ht2c receptor agonists
WO2007119214A3 (en) Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
WO2008087491A8 (en) Method for treating or preventing symptoms of hormonal variations
PT2364142T (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
WO2007150026A3 (en) Purinone derivatives as hm74a agonists
BRPI0925343A2 (en) Compound, pharmaceutical composition, and prophylactic or therapeutic drug
WO2010018549A3 (en) Therapeutic compositions containing macitentan
CL2007003637A1 (en) PROCEDURE FOR THE PREPARATION OF BENZIMIDA PIPERACINILO AND DIAZEPANILO DERIVATIVES USEFUL FOR THE TREATMENT OF DISORDERS AND INTERMEDIATE CONDITIONS BY A HISTAMINE RECEIVER.
UA107334C2 (en) Alkaloid aminoester derivatives and their drug compositions
MX353209B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE.
MX2011008413A (en) Enhanced migraine treatments based on ghrelin mimetics.
IL196094A0 (en) Cyclopropyl amine derivatives as histamin h3 receptor modulators
WO2010120695A3 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
IL201923A0 (en) Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2009118765A8 (en) Novel monoamine re-uptake inhibitor
WO2011043519A3 (en) Sulfonamide derivatives as serotonin receptor antagonist and serotonin reuptake inhibitor
WO2011008666A3 (en) 3-phenoxymethylpyrrolidine compounds
WO2013036015A3 (en) Azetidine derivative and antidepressant composition containing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822164

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC - FORM 1205A (16.07.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10822164

Country of ref document: EP

Kind code of ref document: A2